SLU-PP-332 is an experimental small molecule studied for effects on energy metabolism and exercise endurance in mice. It activates estrogen-related receptors, or ERRs. Despite the common search term “SLU-PP-332 peptide,” it is not a peptide. The research is interesting, but it does not establish a safe human dose, a proven weight-loss treatment or a replacement for exercise. [1][2]

Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see SLU-PP-332 (5 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.

Before interpreting an “exercise in a pill” claim, check the compound and species tested. An experiment in mice isn’t a human treatment result.

What is SLU-PP-332?

SLU-PP-332 is a synthetic research compound that activates all three ERR subtypes: alpha, beta and gamma. An agonist is a substance that activates its target. These receptors help regulate genes involved in cellular energy use. The original development study found the greatest potency at ERR alpha. [1]

A peptide, by contrast, is a short chain of amino acids joined by peptide bonds. Being sold alongside peptides does not make a chemical a peptide. Likewise, appearing in a vial does not tell you its chemical class or whether it is suitable for human use. [5]

Does “estrogen-related” mean it is estrogen?

No. ERRs are related to estrogen receptors in structure, but they do not share the same estrogen-binding behavior. The name should not be read as evidence that SLU-PP-332 supplies estrogen, raises testosterone or has a predictable effect on sex hormones in people. [2]

SLU-PP-332 is a small molecule studied for ERR activation and changes in energy-related gene expression in cells and mice.
SLU-PP-332 research links ERR activation with energy-related gene expression. The pathway shown is a schematic of cell and mouse research, not an established human benefit. See source. AI-generated educational schematic, not a study image.

What does the preclinical research show?

SLU-PP-332 research: what was tested and what remains unproven
Research setting Finding and limit
Muscle cells and mice, 2023 Researchers observed changes in mitochondrial function, oxidative muscle fibers and mouse exercise endurance. [1]
Limit: These were not human athletic-performance results.
Mouse metabolic models, 2024 Experiments found increased energy expenditure and fatty acid oxidation, with favorable body-composition findings in obesity models. [2]
Limit: Results depended on the model; not every measure improved.
Oral exercise-mimetic research, 2026 A different compound, SLU-PP-915, improved exercise capacity in mice after oral administration. [3]
Limit: This does not establish that SLU-PP-332 capsules have the same effect.

Endurance is not the same as muscle growth

The 2023 work linked ERR activation to an aerobic-exercise-related genetic response and better endurance in mice. That is a narrower finding than “builds muscle.” It does not establish increased strength, larger muscles or improved recovery in people who lift weights. [1]

The original paper also disclosed that several authors held stock in a company developing ERR-based therapeutics. That does not invalidate the results, but it makes independent replication an important part of the evidence picture. [1]

Weight and glucose findings were not uniform

In the metabolic study, ordinary chow-fed mice did not show a change in total body weight or improved glucose tolerance. Diet-induced obese mice had more favorable weight and metabolic outcomes. A headline that drops the mouse model can make these findings sound more consistent and transferable than they are. [2]

Quick check: does more fat oxidation prove human weight loss?

No. A change in fuel use is one measurement. Demonstrating sustained weight loss in people requires human studies that measure the outcome, compare groups and assess harms. A mouse experiment cannot supply all three.

Does SLU-PP-332 work orally?

The clearest distinction comes from a study published in the January 2026 issue of the Journal of Pharmacology and Experimental Therapeutics. Its authors described SLU-PP-332 as lacking oral bioavailability and investigated a chemically distinct, orally active compound called SLU-PP-915. [3]

In that mouse work, 915 retained exercise-mimetic activity when given orally. That is a result for 915, not permission to substitute “332” in a capsule advertisement. Similar names and a shared receptor target do not make the compounds interchangeable. [3]

Bioavailability describes how much of a substance reaches the circulation after administration. Even favorable absorption data would not, by itself, prove that a product improves health or is safe. A formulation still needs its own evidence.

Can an exercise mimetic replace exercise?

Not on the evidence reviewed here. “Exercise mimetic” means that a compound reproduces some exercise-associated signals or effects. It does not mean it reproduces everything that happens during physical activity.

A 2026 review describes exercise as a whole-body process involving mitochondrial health, blood-vessel function, autonomic balance, inflammation and signaling between tissues. The authors discuss substantial gaps between experimental compounds and therapeutic use. That is different from a clinical trial showing that a pill replaces training. [4]

For a reader, the practical test is simple: ask which benefit was measured. A change in a muscle-cell pathway is not the same outcome as improved walking ability, fewer cardiovascular events or better quality of life.

SLU-PP-332 side effects and safety gaps

The cited studies do not provide a reliable human side-effect rate or an established treatment schedule. They cannot tell us which medicines might interact with it, how repeated exposure affects people with chronic illness, or what happens over years rather than weeks.

Reports that someone “felt fine” do not resolve those questions. Nor should a list of possible symptoms be presented as though a clinical trial measured their frequency. Unknown risk is not the same thing as confirmed safety.

Product quality is a separate issue. The FDA explains that compounded drugs do not undergo its premarket approval review and that contamination or incorrect strength can cause serious harm. This is general guidance, not evidence of a particular SLU-PP-332 adverse-event rate. A research label or purity claim is not a clinical safety assessment. [6]

Common questions

How long does SLU-PP-332 take to work?

There is no established human timeline in the studies discussed here. The timing of a mouse response should not be turned into a promise about when a person will notice fat loss, more energy or improved endurance.

Is there an evidence-based human dosage?

The research reviewed here does not establish one. Converting a mouse amount by body weight does not validate a human dose, route or cycle. A concentration calculation answers a measurement question, not whether an exposure is medically appropriate.

Is it a SARM or a steroid?

It is described in the research as an ERR agonist, not a selective androgen receptor modulator. Those are different targets. Grouping experimental products together in fitness discussions does not make their mechanisms or risks equivalent. [1]

What would make the evidence stronger?

Independent replication, careful toxicology, human pharmacokinetic studies and controlled human trials with meaningful outcomes. A persuasive trial would report harms as well as benefits and identify the exact compound and formulation.

SLU-PP-332 is a research lead, not a demonstrated replacement for exercise. Check the compound, species and measured outcome behind each claim. A qualified healthcare professional can help assess weight concerns, fatigue or exercise limitations rather than substituting a research chemical for established care.

References

  1. Billon C, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology. 2023. Cell and mouse experiments.
  2. Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024. Mouse study.
  3. Billon C, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics. 2026. Distinct compound; mouse research.
  4. Plaza-Florido A, et al. Exercise pills for cardiometabolic health cannot mimic the exercise milieu. Trends in Endocrinology & Metabolism. 2026. Review.
  5. National Human Genome Research Institute. Peptide. Genetics glossary.
  6. U.S. Food and Drug Administration. Understanding the risks of compounded drugs. General product-quality guidance.

Related dosage protocols and research

Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.

Matching dosage protocols

Further research context

Core guides